Australia markets closed

MRVI Jan 2025 12.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.50000.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Previous close0.5000
Open0.5000
Bid0.2000
Ask0.9500
Strike12.50
Expiry date2025-01-17
Day's range0.5000 - 0.5000
Contract rangeN/A
Volume1
Open interest72
  • GuruFocus.com

    Steven Cohen's Strategic Acquisition in Maravai LifeSciences Holdings Inc

    On June 7, 2024, Steven Cohen (Trades, Portfolio)'s firm made a significant addition to its investment portfolio by acquiring 6,647,015 shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI). This move has increased the firm's stake in Maravai LifeSciences to 5.00% of the total shares outstanding, reflecting a strategic position with a 0.14% portfolio weight and a trade impact of 0.11%. Steven A. Cohen, Chairman and CEO of Point72, a prominent investment advisor, has a distinguished career in the financial markets.

  • Zacks

    Maravai (MRVI) Advances in RNA Research With New Collaboration

    Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.

  • Business Wire

    TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

    SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.